Pharmafile Logo
Pharmafocus logo
Advanced Search

Cladribine

Showing 15 posts of 19 posts found.

mavenclad

NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic

March 3, 2021
Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis

NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …

News

Merck Serono sets up cancer platform

July 3, 2013
Research and Development, Sales and Marketing Cancer, Cladribine, Merck Serono, kgaa

Merck Serono is attempting to speed up R&D on products which stimulate the immune system to fight cancer by establishing …

News

Merck KGaA swings axe over Serono operations

April 25, 2012
Manufacturing and Production, Research and Development, Sales and Marketing Cladribine, MS, Merck KGaA, Switzerland, job cuts

Merck KGaA will cut around 500 jobs from its pharmaceutical unit in Switzerland, the firm has announced.  The company said …

News
Merck Serono

Merck licences new MS drug

September 19, 2011
Research and Development Cladribine, Merck KGaA, Merck Serono, PI-2301

Merck KGaA has in-licensed a new multiple sclerosis drug and aims to start it in phase II studies later this …

News
Merck KGaA

Merck scraps MS pill cladribine

June 23, 2011
Research and Development, Sales and Marketing Cladribine, Merck KGaA, Movectro, multiple sclerosis

Merck KGaA has pulled all pending applications for its multiple sclerosis pill Movectro and will withdraw it from the markets …

News
EMD Serono headquarters

FDA knocks back Merck KGaA’s oral MS drug

March 2, 2011
Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs

US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …

News
Merck KGaA

Merck KGaA sales soar

February 21, 2011
Sales and Marketing 2010 pharma results, Cladribine, Merck KGaA, Merck Serono, Movectro

Merck KGaA’s sales jumped last year by nearly a fifth as recent acquisitions and strong growth on core products set …

News
Merck Serono headquarters

Merck Serono halts Movectro European licence application

February 18, 2011
Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …

News

Novartis MS drug steals march over Merck rival

January 24, 2011
Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis

Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …

News

Key drug launches for 2011

January 20, 2011
Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir

This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …

Feature

Europe committee rejects MS treatment Movectro

September 24, 2010
Sales and Marketing Cladribine, Merck Serono Movectro

The Europe Medicines Agency has rejected Merck Serono’s new multiple sclerosis treatment Movectro, saying its benefits do not outweigh its …

News

Gilenya approved as new frontline MS treatment

September 22, 2010
Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya

Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …

News

Gilenya approved in Russia, awaits FDA decision

September 16, 2010
Sales and Marketing Cladribine, Gilena, MS

Novartis has won approval for its MS drug Gilenya in Russia but still awaits the FDA’s decision on its fate …

News

Merck KGaA’s oral MS therapy gains US priority review

July 29, 2010
Sales and Marketing Cladribine, MS, Merck KGaA

Merck’s cladribine has been granted a priority review status by the FDA in a move that could see it come …

News

First oral MS treatment approved in Russia

July 12, 2010
Sales and Marketing Cladribine, MS, Merck Serono, Movectro

Regulators in Russia have approved Merck Serono’s cladribine, lining up the drug to be the first oral treatment for multiple …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024